AbbVie Surges Past Earnings Estimates: Is This the Next Big Win for Investors?
AbbVie achieved Q4 revenues of $15.1 billion, surpassing analyst forecasts. Adjusted earnings per share were $2.16, exceeding expectations. The company experienced strong demand for its immunology drugs, Rinvoq and Skyrizi. Despite a